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Abstract
Background Gastric secretion can provide valuable infor-
mation especially when Helicobacter pylori (Hp) infection
results in chronic atrophic gastritis (CAG) and intestinal
metaplasia (IM) preceding adenocarcinoma (AdCa).
Aims Looking for a potential biomarker of malignant
transformation in the setting of chronic inﬂammation we
studied the levels of prostaglandin E2 (PGE2), as well as
peptide growth factors [epidermal growth factor (EGF) and
transforming growth factor a (TGFa)], harbingers of injury
and repair, in gastric juice aspirated at endoscopy from
patients with CAG, CAG/IM, AdCa, and controls.
Methods The PGE2, EGF and TGFa concentrations in the
gastricjuiceweremeasuredusingradioimmunoassays(RIAs).
Results In patients with AdCa gastric juice PGE2
increased ﬁvefold versus controls (P\0.01) and almost
threefold versus patients with CAG (P\0.05). The EGF
levels in patients with AdCa were fourfold higher versus
controls (P\0.001) and almost threefold higher versus
CAG (P\0.05). In patients with CAG/IM the EGF levels
were also almost 3 times higher versus controls. The TGFa
levels in patients with AdCa were half the value of controls
and CAG (P\0.05). In patients with CAG/IM the levels
were as low as 1/5 of controls or CAG (P\0.05).
Conclusions Testing the gastric juice for PGE2, EGF, and
TGFa in patients with endoscopy and biopsy proven CAG,
may be helpful in follow up of patients who may poten-
tially progress to IM and ultimately AdCa. This could be
considered as an adjunct to histologic assessment espe-
cially that even the best surveillance biopsy specimen
regimens are inherited with sampling errors.
Keywords Gastritis  Intestinal metaplasia 
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Introduction
The integrity of the gastrointestinal mucosa depends upon
equilibrium between aggressive factors and protective
mechanisms [1–3]. Among aggressive factors gastric acid
and pepsins are the culprits of injury, whereas PGE2 and
peptide growth factors such as EGF and TGFa are the
dominant protective molecules [4–8].
Colonization of gastric mucosa with Hp profoundly
changes this equilibrium mainly through generation of
acute and subsequently chronic inﬂammation and secretion
of its toxins and various enzymes [4–8].
The concentration of PGE2, EGF and TGFa in the
gastric juice reﬂects the rate of the production by the
gastric mucosa, their subsequent binding to the receptors
on the luminal aspect of the surface epithelium and their
proteolytic degradation by gastric acid and pepsin as well
as enzymes generated by Hp [9].
The aggressive factors induced gastric mucosal injury
resulting in loss of mucosal barrier can be quickly healed if
adequate supply of PGE2, EGF and TGFa takes place.
Therefore the measurement of PGE2, EGF and TGFa in the
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injured cell epithelium and repair as well as restoration of
the mucosal barrier. This is especially an important con-
sideration given the fact that within the gastric mucosal
milieu there is always a very powerful and protective
endogenous barrier against the aggressive factors espe-
cially acid and pepsin [9]. We have therefore studied the
concentration of PGE2, EGF and TGFa in gastric juice
aspirated at the onset of surveillance endoscopy in patients
colonized with Hp in the past with subsequent CAG, IM
and gastric AdCa and compared the levels with those with
Hp negative controls. This way we have utilized a sample
of gastric juice, which would have been discarded
otherwise.
Our data represent a proof of concept that the concen-
trations of PGE2, EGF, or TGFa may differ at various
stages of gastric mucosal pathology related to the past
history of colonization with H. pylori.
Materials and Methods
Subjects
The study was approved by the Human Investigation
Committee at KUMC. Informed consent was obtained from
all subjects. Twenty eight consecutive patients referred for
upper GI endoscopy for surveillance and with symptoms of
non-ulcer dyspepsia were enrolled in the study. All patients
had Hp-induced CAG or CAG/IM or CAG/IM/AdCa as
conﬁrmed by the endoscopy and gastric biopsy, although
they received Hp eradication. Successful H. pylori eradi-
cation was conﬁrmed by
14C-urea breath test.
Among recruited patients 16 were M and 12 F. Of the 28
subjects11hadCAG(6M&5F),8hadCAG/IM(5M&3F)
and 9 patients had Gastric AdCa (5 M & 4 F). The mean age
of the population was 55 years (range 30–65 years). There
were 13 Hp negative controls with symptoms of non-ulcer
dyspepsia (7 M & 6 F, mean age of 52, 28–64 range) with
normal endoscopy and histology.
All subjects represent outpatient’s population within the
Endoscopy Center. Patients were advised not to eat and
drink after midnight. Patients were not taking non-steroidal
anti-inﬂammatory drugs as well as antisecretory medica-
tion for at least 1 week before endoscopy. All patients were
prepared for endoscopy using the same standardized pro-
cedure. None medication, including antacids, was allowed
on the day of endoscopy.
The biopsy sampling and degree of gastritis was asses-
sed according to Sydney System, 1996. Brieﬂy, 1 specimen
was obtained from the lesser and 1 from the greater cur-
vature of the antrum, both within 2–3 cm from the pylorus;
1 sample from the lesser curvature of the corpus approxi-
mately 4 cm proximal to the angulus, 1 sample from the
middle portion of the greater curvature of the corpus, about
8 cm from the cardia and 1 sample from the incisura
angularis’’.
Even more than 1 year after successful H. pylori erad-
ication, in a great majority of patients at least moderate
inﬁltration with chronic inﬂammatory cells was recorded
and was similar in three investigated groups. Atrophy of
the gastric body mucosa was deﬁned as focal or diffuse
oxyntic gland loss and/or replacement by metaplastic
pyloric or intestinal glands. Atrophy of the gastric antral
mucosa was deﬁned as focal or complete replacement of
antral glands with intestinal metaplastic epithelium. Pre-
sented patients with gastritis were diagnosed as moderate
or severe gastritis with or without type III of intestinal
metaplasia.
The age, gender and the smoker status distribution was
similar in all subgroups and none of them were drinking
more than 1–2 drinks per day. H. pylori eradication was
implemented at least 1 year ago. Gastric cancer was found
on the lesser curvature and around the angulus, measured
between 2 and 5 cm and histologically represented the
intestinal type of adenocarcinoma, T1 or T2, all well or
moderately well differentiated.
At the time of endoscopy gastric juice present within the
stomach was aspirated into a container, iced, assessed
volumetrically and processed immediately.
All samples were centrifuged at 3,000 rpm (2,500g) for
30 min, conditions required to spin down cell debris such
as plasma membrane sheets and nuclei (Sorvall RT 6000
Refrigerated Centrifuge, Rotor H1000, Newtown, CT). All
samples were centrifuged at 4C.
Methods
Measurement of PGE2
PGE2 in the gastric juice was measured as the methyloxime
by the radioimmunoassay (RIA) using a novel iodinated
label (Amersham, Arlington Heights, IL) developed by
Kelly et al. [10] as described recently [11, 12]. The
advantage of this method is that the imide linkage of the
methyl oxime to proline results in an equal afﬁnity of
antiserum for the labeled oximated PGE2 and compound to
be measured. Methyloximation also protects PGE2 from
dehydration during the assay. The sample extraction step
through C18 columns provides a high degree of homoge-
neity and it also maintains near 100% recovery of added
PGE2. We achieved very good intraassay (3.4%) and
interassay (5.8%) variations [11].
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The pH of gastric secretion was recorded with an
expandable Ion Analyzer (model AE 940; Orion, MA) and
pH of gastric juice was adjusted to pH 7.4 before the
measurement of EGF and TGFa. Measurements of EGF
and TGFa were performed by RIA using a commercially
available kit (Amersham, IL). This assay is based on the
highly speciﬁc rabbit anti-human RGF and TGFa anti-
bodies, which do not exhibit cross-reactivity with a large
variety of structurally unrelated gut peptides such as gas-
trin, somatostatin, secretin, or pancreatic polypeptide [7, 8].
Anti-human EGF and TGF a antibodies showed an 88%
cross reactivity with the mouse EGF but not rat TGFa (0%
cross-reactivity). Human EGF antiserum was used at a
dilution of 1:20,000. The separation between bound and
unbound EGF was performed with a use of Amerlex-M
second antibody. In the ﬁnal calculations of EGF and TGFa
concentrations, non speciﬁc binding was always consid-
ered. Human recombinant EGF (Amgen, CA) was used for
a standard curve.
Statistical Analysis
All results are presented as the mean ± SEM. Statistical
analysis of variance (ANOVA) was performed using
Sigma-Stat (Jandel Scientiﬁc, San Rafael, CA).
Results
Gastric Juice PGE2
The levels of PGE2 (Fig. 1) in patients with CAG/IM/Ad
Ca were over 2,000 pg/ml, i.e. a ﬁvefold elevation, as
compared to the controls (P\0.01). When compared to
the group with CAG the levels in patients with CAG/IM/
AdCa were about threefolds higher (P\0.05). The levels
were also high in patients with CAG/IM, about threefold as
compared to the controls. In patients with CAG the levels
were almost twofold higher than in controls.
Gastric Juice EGF
The concentration of EGF (Fig. 2) in gastric secretion of
patients with CAG/IM/AdCa was over fourfold higher
than the controls (6.4 ng/ml vs. 1.6 ng/ml, P\0.001) and
threefold higher in comparison to the CAG group
(P\0.05). The levels were also elevated in CAG/IM
although to a much lower concentration than those with
AdCa, reaching about threefold increase as compared to the
controls. The results of EGF in the samples obtained from
CAG were about 1/3 higher than in controls.
Gastric Juice TGFa
Intriguingly, the levels of TGFa (Fig. 3) in patients with
CAG/IM were as low as 1/5th of the control group or
patients with CAG (P\0.05). The levels were as low as
0.07 ng/ml in this subset of patients. The concentration of
TGFa in patients with CAG/IM/AdCa were half the value
of controls and CAG (P\0.05), but increased almost
threefold from the lowest value recorded in patients with
CAG/IM. However the TGFa levels in CAG were quite
similar to values in controls.
Fig. 1 Gastric Juice prostaglandin E2 in controls (Ctrl), chronic
atrophic gastritis (CAG), chronic atrophic gastritis/intestinal meta-
plasia (CAG/IM), and chronic atrophic gastritis/intestinal metaplasia/
adenocarcinoma (CAG/IM/AdCa)
Fig. 2 Gastric juice EGF in controls (Ctrl), chronic atrophic gastritis
(CAG), chronic atrophic gastritis/intestinal metaplasia (CAG/IM),
and chronic atrophic gastritis/intestinal metaplasia/adenocarcinoma
(CAG/IM/AdCa)
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Chronic inﬂammation has been well implicated in the eti-
ology of alimentary tract cancer. Key molecular players
that link inﬂammation to carcinogenesis are prostaglandins,
cytokines, nuclear factor –jB, chemokines, angiogenic
growth factors and free radicals as well as gene products
which contribute to multistage of carcinogenesis through
activation of oncogenic products and/or inhibition of tumor
suppressor genes [13]. Though inﬂammation includes
injury, repair and resolution; all inﬂammatory cells may
also contribute to carcinogenesis [14]. Inﬂammatory stim-
uli include chemicals, foreign bodies and infectious
organisms such as Helicobacter pylori (Hp), Ebstein Barr
virus among others [15].
Hp has been linked epidemiologically to gastric and
duodenal ulcers, gastric cancer and gastric mucosa-asso-
ciated lymphoid tissue (MALT) lymphoma [16–18]. Hp
induced CAG is a prerequisite for the formation of pre-
neoplastic and malignant lesions, both in humans and in
rodent models of Hp-induced disease [19, 20]. The trans-
formation from normal mucosa to gastric cancer occurs via
a sequence of precursor lesions starting with CAG, IM and
dysplasia [21].
Inﬂammation and carcinogenesis share a common
molecular mediator, the cyclooxygenase (COX) enzymes
COX-1 and COX-2 which generate their major product
PGE2, exerting its effects by binding to the ubiquitously
expressed the E prostanoid receptors 1–4 [22, 23].
COX-2–dependent pathways play a role in carcino-
genesis, especially in the gastrointestinal tract [24, 25].
The long-term low-level intake of nonsteroidal anti-
inﬂammatory drugs inhibiting COX activity reduces
the risk of gastric and colorectal cancer [26–28]. Tumor-
derived PGE2 is believed to promote cancer progression by
stimulating cell motility/invasion, angiogenesis and by
preventing tumor cell apoptosis [29] through potentiation
and induction of target genes by activation of the EGF
receptor pathway [30]. PGE2 through its strong immuno-
suppressive effects, may allow tumors to evade immune
surveillance [31].
It is a known fact that COX-1 and COX-2 are widely
expressed in gastric cancers resulting in elevated PGE2
levels which up regulates VEGF expression and this effect
is mediated by the EGFR activation [32–36]. This enhances
the cancer cell invasion and angiogenesis via TLR2 and
TLR9, which can be attenuated by the speciﬁc COX-2
inhibitor NS398 or celecoxib [37].
Our study clearly substantiates the above concepts of a
link between prostaglandin E2 and carcinogenesis. The
levels of PGE2 were signiﬁcantly higher in CAG/IM/AdCa
and the levels showed a proportional increase in CAG and
CAG/IM. This conﬁrms the ﬁndings that PGE2 in the
gastric mucosa and plasma is increased in all patients with
gastric cancer, especially with metastasis and it correlates
well with age, stage, histological pattern of tumor, its dif-
ferentiation and inﬁltration [38, 39].
The gastrointestinal tract possesses the remarkable
ability to withstand injury resulting in cell migration (res-
titution), followed by an increase in proliferation and
remodeling with at least 30 different peptides being
involved in stimulating the repair process. In general
peptides can be compartmentalized into: (1) mucosal
integrity peptides which are predominantly involved in
maintaining mucosal morphology e.g., TGFa (2) luminal
surveillance peptides which stimulate proliferation and
repair at sites of injury e.g., EGF and (3) rapid response
repair peptides whose production is rapidly regulated at
sites of injury [40].
EGF, a potent stimulant of proliferation, migration and
gut repair is most effective when it can bind to its receptor
predominantly located on the basolateral membrane which
is easily accessible at the site of injury [41–44]. TGFa is a
potent stimulant of proliferation and differentiation acting
via the EGF receptor too (EGF-R or c-erb2) [40].
EGF family growth factors including TGFa have been
proposed as integrative cytoprotective factors against
gastric injury [37, 45], through stimulation of cell prolif-
eration, migration, inhibition gastric acid secretion and
increasing the release of mucus [46–48], which is greatly
affected by sialoadenectomy in experimental animals
[49, 50].
Gastric cancer patients show an increased expression of
EGF and TGFa but their gastric acid secretion is markedly
reduced possibly due to atrophy of oxyntic mucosa.
Fig. 3 Gastric juice TGFa in controls (Ctrl), chronic atrophic
gastritis (CAG), chronic atrophic gastritis/intestinal metaplasia
(CAG/IM), and chronic atrophic gastritis/intestinal metaplasia/adeno-
carcinoma (CAG/IM/AdCa)
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as reduced gastric acid secretion due to gastric mucosal
atrophy may be implicated in the pathogenesis of gastric
cancer [51].
In our study there is a signiﬁcant increase in the EGF
levels which in concordance with the declining levels of
TGFa would beneﬁt to detect those transforming from
CAG to CAG/IM and eventually to gastric carcinoma.
Very high levels of EGF were found in patients with AdCa,
almost a ﬁvefold increase in the concentration compared to
the two to threefold rise in CAG and CAG/IM.
Our analysis of gastric juice samples also shows the
signiﬁcant reduction in the TGFa level, which conﬁrms the
potential cytoprotective value of this growth factor against
development of gastric neoplasm in the setting of CAG/IM.
Signiﬁcant reduction in the levels of TGFa in CAG/IM
tissue may facilitate its transformation into gastric cancer.
This important aspect during the analysis of the gastric
juice should be borne in mind in patients with CAG and
with very low levels of TGFa, who could be progressing
towards IM vis-a `-vis AdCa.
From our analysis of gastric juice samples we conclude
that a step wise increase in the PGE2 starting from normal
and going through phases of CAG, CAG/IM and ultimately
to CAG/IM/AdCa provides a good evidence that testing its
content in samples aspirated during surveillance endoscopy
could be of value in their predictive potential before and
during the development of AdCa. This however requires
further investigation. In a similar way simultaneously
measuring the concentration of growth factors such as EGF
and TGFa will provide us clue as to the underlying disease
progression. As noted above in our discussion EGF levels
closely parallel the PGE2 levels showing a step wise
increase from controls through stages of CAG, CAG/IM
and CAG/IM/AdCa. However the levels of TGFa are
conversely reduced as the condition progresses from CAG
through CAG/IM and CAG/IM/AdCa thereby concurring
with several studies done earlier on its protective values
[44, 45].
Although in our study subjects the Hp was eradicated
prior to the screening endoscopy, it takes several years for
most of the patients with CAG to signiﬁcantly improve the
gastric morphology despite eradication. Therefore although
our patients had Hp negative CAG, CAG/IM and CAG/IM/
AdCa the gastric juice analysis of PGE2, EGF and TGFa
still reﬂect the ongoing chronic inﬂammatory changes
within the gastric mucosa. Hence to eliminate the potential
detrimental impact of Hp colonization and subsequent
development of chronic inﬂammation leading to no return
to the original normal morphology but rather going on to
CAG, CAG/IM and the dreaded complication of gastric
AdCa it is highly advisable to treat young people at an
early age especially in countries with high endemicity of
Hp. This is the only way to prevent the potential chronic
complications associated with Hp the most notable being
the gastric AdCa.
In conclusion, testing the gastric juice for EGF, TGFa
and PGE2 in patients with endoscopy and biopsy proven
CAG, due to Hp may be helpful in follow up of these
patients who may potentially progress to IM and ultimately
to AdCa. This could be considered as an adjunct to histo-
logic assessment especially given the fact that even the best
biopsy specimen regimens during surveillance are inherited
with signiﬁcant sampling errors.
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